{"contentid": 488702, "importid": NaN, "name": "Batch of new drug EMA/CHMP recommendations for May 2021", "introduction": "Following its May 2021 meetings, the European Medicines Agency\u00e2\u0080\u0099s human medicines committee (CHMP) recommended eight even medicines, including one gene therapy and one generic, for approval.", "content": "<p>Following its May 2021 meetings, the European Medicines Agency&rsquo;s human medicines committee (CHMP) recommended eight even medicines, including one gene therapy and one generic, for approval. Final decisions on approval will be announced by the European Commission, which usually occurs within two or three months.</p>\n<p>The Committee recommended granting a marketing authorization for <strong>Skysona</strong> (elivaldogene autotemcel), from US biotech bluebird bio (Nasdaq: BLUE), for the treatment of early cerebral adrenoleukodystrophy (CALD) for patients without a matched sibling hematopoietic stem cell donor. As Skysona is a gene therapy, the CHMP&rsquo;s positive opinion is based on an assessment by the EMA&rsquo;s Committee for Advanced Therapies (CAT).</p>\n<p>The Committee adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for <strong>Bylvay</strong> (odevixibat), from US firm Albireo Pharma (Nasdaq: ALBO), for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged six months or older, and could be the first non-surgical treatment for this rare disease if it gains final approval.&nbsp;</p>\n<p><strong>Imcivree </strong>(setmelanotide), from Rhythm Pharmaceuticals (Nasdaq: RYTM), was granted a positive opinion by the Committee for the treatment of obesity and the control of hunger associated with genetic deficiencies of the melanocortin 4 receptor (MC4R) pathway.</p>\n<p><strong>Klisyri</strong> (tirbanibulin mesylate), from Spanish drugmaker Almirall (ALM: MC), was granted a positive opinion for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis on the face or scalp. Treatment is a critical aspect of the disease as it may progress to invasive squamous cell carcinoma (SCC).</p>\n<p>The CHMP adopted a positive opinion for <strong>Ozawade</strong> (pitolisant), from French drugmaker Bioproject Pharma, for the treatment of excessive daytime sleepiness in obstructive sleep apnoea.</p>\n<p>The Committee adopted a positive opinion for<strong> Ryeqo</strong> (relugolix/estradiol/norethisterone acetate), from Hungary&rsquo;s largest drugmaker Gedeon Richter (RICHT: HB), for the treatment of symptoms of uterine fibroids in adult women of reproductive age.</p>\n<p>German pharma major Bayer&rsquo;s (BAYN: DE) <strong>Verquvo</strong> (vericiguat) was granted a positive opinion by the Committee for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction.</p>\n<p>The CHMP recommended granting a marketing authorization for one generic medicine: <strong>Icatibant Accord </strong>(icatibant), from Accord Healthcare, for the treatment of acute attacks of hereditary angioedema.</p>\n<p>Image:&nbsp;ema_building-credit_rob_acket.</p>", "date": "2021-05-21 15:49:00", "meta_title": "Batch of new drug EMA/CHMP recommendations for May 2021", "meta_keywords": "EMA, CHMP, Recommendations, bluebird bio, Skysona, Albireo, Bylvay, Rythym Pharma, Imcivree", "meta_description": "Batch of new drug EMA/CHMP recommendations for May 2021", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-21 15:48:39", "updated": "2021-05-25 09:17:23", "access": NaN, "url": "https://www.thepharmaletter.com/article/batch-of-new-drug-ema-chmp-recommendations-for-may-2021", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "ema_building-credit_rob_acket.jpg", "image2id": "ema_building-credit_rob_acket_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology, Pharmaceutical", "therapy area_tag": "Cardio-vascular, Cell and Gene Therapy, CNS Diseases, Dermatologicals, Metabolics, Rare diseases, Women's health", "topic_tag": "European Medicines Agency, Focus On, Regulation", "geography_tag": "Europe", "company_tag": "Accord Healthcare, Albireo, Almirall, Bayer, Bioproject Pharma, bluebird bio, Gedeon Richter, Rhythm Pharmaceuticals", "drug_tag": "Bylvay, Imcivree, Klisyri, Ozawade, Ryego, Skysona, Verquvo", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-21 15:49:00"}